title: Complete resolution of transplantation-associated thrombotic microangiopathy and hepatic veno-occlusive disease by defibrotide and plasma exchange.
abstract: Transplantation-associated thrombotic microangiopathy has been associated with significantly reduced survival following allogeneic bone marrow transplantation. We describe here the course of Transplantation-associated thrombotic microangiopathy and hepatic veno-occlusive disease, and response to plasma exchange therapy. A 19-year-old male patient underwent hematopoietic stem cell transplantation (HSCT) from his HLA-matched brother for lymphoblastic lymphoma in the first complete remission. Transplantation-associated thrombotic microangiopathy was diagnosed 17 days after transplantation. At that time, neurological abnormalities were not present. Cyclosporin A (CsA) was discontinued. Hematological stabilization was recorded. On day +20, abdominal distention, painful hepatomegaly and ascites complicated the clinical picture. With a high hepatic venous pressure gradient (18mmH20), veno-occlusive disease of the liver was diagnosed and defibrotide was started, which resulted in a dramatic cessation of pain and increase in urinary output. However, transplantation-associated thrombotic microangiopathy-related symptoms progressed and plasma exchange was instituted, which resulted in worsening of veno-occlusive disease symptoms. He was referred to the Intensive Care Unit due to respiratory compromise and was intubated. Plasma exchange was continued in order after hemofiltration. In three days, fever resolved, hemofiltration could be stopped, and ventilator dependence ended. After 19 aphereses, serum LDH level returned to normal and schistocytes were minimal on microscopic examination of the blood film. Platelet count increase was more gradual. Plasma exchange was discontinued. On the 40th day of defibrotide, all symptoms related with veno-occlusive disease were resolved and defibrotide was stopped. We think that our case is important to establish the relation and management strategy of these two small vessel complications of HSCT.
authors.affiliation: Department of Internal Medicine, Division of Hematology, Faculty of Medicine, Istanbul University, Istanbul, Turkey. sevgikalayoglu@yahoo.com
authors.forename: Sevgi Kalayoğlu
authors.initials: SK
authors.lastname: Beşişik
authors.forename: Gülistan Bahat
authors.initials: GB
authors.lastname: Oztürk
authors.forename: Yaşar
authors.initials: Y
authors.lastname: Calişkan
authors.forename: Deniz
authors.initials: D
authors.lastname: Sargin
mesh_terms: D000328:Adult; D006502:Budd-Chiari Syndrome / Q000209:etiology / Q000628:therapy*; D005500:Follow-Up Studies; D006504:Hepatic Veno-Occlusive Disease / Q000209:etiology / Q000628:therapy*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy; D008297:Male; D008833:Microcirculation; D036102:Peripheral Blood Stem Cell Transplantation / Q000009:adverse effects*; D010951:Plasma Exchange; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011089:Polydeoxyribonucleotides / Q000627:therapeutic use*
chemical_list: D010975:Platelet Aggregation Inhibitors; D011089:Polydeoxyribonucleotides; C036901:defibrotide